This family protocol summary is intended to provide a general overview of the Children's Oncology Group study ARET0321. It will provide information about the children that are eligible for this study and basic information regarding the specifics of the study. The informed consent and protocol contain the full details of the study. Those documents are available to you from your oncologist.

ARET0321 is a Phase 3 clinical trial. A trial is another word for a study. This study (clinical trial) is a therapeutic clinical trial. That means it is done to learn about treatment – its safety and how well it works. The purpose of a Phase III trial is to learn if a new treatment that is known to work in treating a type of cancer is better in some way than the standard treatment. For example, does it have better cure rates, longer control of disease, fewer or less serious side effects, or fewer days in the hospital?

ARET0321 compares two treatments. These treatments are called study arms. Usually, one study arm is the standard or the best proven current treatment. The other study arm has some changes or additions. The new treatment is thought to be at least as good as the standard treatment. It is not known if the new treatment will be better than the standard treatment.

In a Phase 3 trial, each child is assigned to a study arm by a method called randomization. This is a process like flipping a coin that assures that each child has a fair and equal chance of being assigned to any of the study arms. This makes sure the study arms can be compared fairly.

In most clinical trials, we will not know which treatment is better until all of the children taking part in the trial have completed treatment and have been getting checked for several years. If one of the treatments is found to be better or safer than the others while the trial is still going on, the trial will be stopped. All children still in the trial will be given the treatment with the best results when possible.

It is important to understand that participating in a clinical trial is entirely voluntary. The decision about whether or not to participate will not affect the care provided by the health care team in any way. You can find additional information about participation in clinical trials at Always discuss any questions that you may have with your health care team.

Study Number


Official Title

A Trial of Intensive Multi Modality Therapy for Extra- Ocular Retinoblastoma

Study Opening Date

ARET0321 opened 2/4/2008. The ARET0321 committee plans to enroll 90 patients. It is expected that this study will remain open for six years.

Study Closing Date

Study ARET 0321 reached accrual goals and was closed to further patient entry as of 11/11/2014.

General Patient Eligibility


General Background and Study Goal

Researchers want to know if they can improve the cure rate for extra-ocular retinoblastoma by giving more intensive (stronger) therapy. The overall goal of this study is:


Summary of the Treatment

The treatment plan involves cancer fighting medicine called chemotherapy. The treatment on this clinical trial takes about 6 to 8 months. Multiple chemotherapy medicines are given. This chemotherapy is given intravenously primarily as an inpatient. The treatment plan is determined by disease stage:

Patients on this study, stage 2 and 3 will receive:

Patients on this study, stage 4 will receive:


Risks and Side Effects

Chemotherapy and radiation therapy can cause short- and long-term side effects. All patients will be closely monitored to reduce the likelihood of negative side effects. All risks and side effects will be explained in detail by your healthcare team during the consent process. They can answer any questions that you may have regarding participation on the clinical trial or other aspects of care. Please refer to the consent document for a detailed explanation of the side effects associated with the treatment on this study.

Contact Information

Your child's oncologist is the best source for further information. Physicians with eligible patients should refer questions to the principal investigator:

Study Chair

Ira Dunkel, MD
Memorial Sloan- Kettering cancer Center


Initial development Name Date
Written by Diane Baniewicz, MSN, CPNP, CPON February, 2014
Reviewed/approved by (PI) Ira Dunkel, MD February, 2014
Ongoing review
Reviewed and updated by Diane Baniewicz, MSN, CPNP, CPON December 8, 2016

© The Children's Oncology Group
The information and content provided on this website is made available for informational purposes only for children and their families affected by cancer. While the Children's Oncology Group strives to provide accurate and up-to-date information, the information may be out of date or incomplete in certain respects. Please do not rely on this information and seek the care of a qualified medical professional if you have questions regarding a specific medical condition, disease, diagnosis or symptom. The information and content presented herein is not intended to replace the independent clinical judgement, medical advice, screening, health counseling, or other intervention performed by your (or your child's) health care provider. Please contact "911" or your emergency services if this is a health emergency. No endorsement of any specific tests, products, or procedures is made herein.